Haixiang Pharmaceutical announced that on June 22, 2026, the board of directors of the company reviewed and approved the share repurchase plan. It plans to use 150 million yuan to 300 million yuan of own/self-raised capital to centrally bid back shares at a price of no more than 8.55 yuan/share for equity incentives or employee stock ownership plans. The repurchase period is 12 months from the date of review and approval by the board of directors. As of October 31, 2026, the company had repurchased a total of 24.1611 million shares, accounting for 1.49% of the total share capital. The highest transaction price was 5.44 yuan/share, the lowest transaction price was 4.91 yuan/share, and the total transaction amount was 123 million yuan. Subsequent companies will continue to advance the repurchase plan during the repurchase period.

Haixiang Pharmaceutical announced that on June 22, 2026, the board of directors of the company reviewed and approved the share repurchase plan. It plans to use 150 million yuan to 300 million yuan of own/self-raised capital to centrally bid back shares at a price of no more than 8.55 yuan/share for equity incentives or employee stock ownership plans. The repurchase period is 12 months from the date of review and approval by the board of directors. As of October 31, 2026, the company had repurchased a total of 24.1611 million shares, accounting for 1.49% of the total share capital. The highest transaction price was 5.44 yuan/share, the lowest transaction price was 4.91 yuan/share, and the total transaction amount was 123 million yuan. Subsequent companies will continue to advance the repurchase plan during the repurchase period.